G6PD and methemoglobinemia: Importantly, this overlap presents a distinct therapeutic challenge: methylene blue, the first-line agent for treating methemoglobinemia, requires nicotinamide adenine dinucleotide phosphate (NADPH) generated by the G6PD pathway, and its administration in G6PD-deficient patients can precipitate hemolysis [7].